These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 28274582)
1. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Jameera Begam A; Jubie S; Nanjan MJ Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582 [TBL] [Abstract][Full Text] [Related]
2. Estrogen signaling: An emanating therapeutic target for breast cancer treatment. Saha T; Makar S; Swetha R; Gutti G; Singh SK Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450 [TBL] [Abstract][Full Text] [Related]
3. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. Pasqualini JR; Chetrite GS J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265 [TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
5. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Jordan VC; Brodie AM Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390 [TBL] [Abstract][Full Text] [Related]
6. Antiestrogens: structure-activity relationships and use in breast cancer treatment. Traboulsi T; El Ezzy M; Gleason JL; Mader S J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460 [TBL] [Abstract][Full Text] [Related]
7. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview. Bhatia N; Hazra S; Thareja S Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948 [TBL] [Abstract][Full Text] [Related]
8. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342 [TBL] [Abstract][Full Text] [Related]
9. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Jordan VC; Lewis JS; Osipo C; Cheng D Breast; 2005 Dec; 14(6):624-30. PubMed ID: 16202599 [TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy for breast cancer: an overview. Cheung KL Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991 [TBL] [Abstract][Full Text] [Related]
11. Progress in the prevention of breast cancer: concept to reality. Jordan VC J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935 [TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Patel HK; Bihani T Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555 [TBL] [Abstract][Full Text] [Related]
13. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer. Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Katzenellenbogen BS; Katzenellenbogen JA Breast Cancer Res; 2000; 2(5):335-44. PubMed ID: 11250726 [TBL] [Abstract][Full Text] [Related]
15. The SEEM: selective estrogen enzyme modulators in breast cancer. Pasqualini JR; Ebert C; Chetrite GS Gynecol Endocrinol; 1999 Dec; 13 Suppl 6():1-8. PubMed ID: 10862262 [TBL] [Abstract][Full Text] [Related]
16. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. McDaniel RE; Maximov PY; Jordan VC Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002 [TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Fan W; Chang J; Fu P Future Med Chem; 2015 Aug; 7(12):1511-9. PubMed ID: 26306654 [TBL] [Abstract][Full Text] [Related]
18. A review of coumarin derivatives in pharmacotherapy of breast cancer. Musa MA; Cooperwood JS; Khan MO Curr Med Chem; 2008; 15(26):2664-79. PubMed ID: 18991629 [TBL] [Abstract][Full Text] [Related]
19. Accelerating drug development in breast cancer: New frontiers for ER inhibition. Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531 [TBL] [Abstract][Full Text] [Related]
20. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. O'Regan RM; Jordan VC Lancet Oncol; 2002 Apr; 3(4):207-14. PubMed ID: 12067682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]